Trial
NCT04024813
A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Gilead Sciences
Collaborators
—
Condition
Primary Sclerosing Cholangitis
Intervention
Seladelpar
Why stopped
Study was terminated as a precautionary measure due to histological findings in a nonalcoholic steatohepatitis (NASH) study (CB8025-21730, NCT03551522).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-16